

HARMONOGRAM KONKURSÓW

Lp.	Termin składania wniosków	Program lub Instytucja finansująca	Nazwa konkursu	Zakres	Link
1	20.05.2019	NARODOWA AGENCJA WYMIANY AKADEMICKIEJ	Program im. Prof. Walczaka - wspólna inicjatywa NAWA oraz Ministerstwa Zdrowia	Program NAWA oraz Ministerstwa Zdrowia skierowany do naukowców z obszaru kardiologii, onkologii, alergologii lub chorób zakaźnych. Program umożliwi im wyjazdy trwające od 3 do 6 miesięcy do najlepszych ośrodków medycznych zlokalizowanych na terenie Stanów Zjednoczonych Ameryki.	https://nawa.gov.pl/nawa/aktualnosci/934-program-im-prof-walczaka-wspolna-inicjatywa-nawa-oraz-ministerstwa-zdrowia
2	01.06.2019	FUNDACJA NAUKOWA POLPHARMY	Poszukiwanie punktów uchwytu dla terapii celowanej z wykorzystaniem układu immunologicznego oraz poszukiwanie mechanizmów oporności na stosowane obecnie metody immunoterapii	Projekty badawcze w dziedzinie nauk farmaceutycznych i medycznych.	www.polpharma.pl/fundacja
3	17.06.2019	NARODOWE CENTRUM NAUKI	OPUS 17	konkurs na projekty badawcze, w tym finansowanie zakupu lub wytworzenia aparatury naukowo-badawczej niezbędnej do realizacji tych projektów	https://www.ncn.gov.pl/ogloszenia/konkursy/opus17
4	17.06.2019	NARODOWE CENTRUM NAUKI	PRELUDIUM 17	konkurs na projekty badawcze realizowane przez osoby rozpoczynające karierę naukową nieposiadające stopnia naukowego doktora	https://www.ncn.gov.pl/ogloszenia/konkursy/preludium17
5	NABÓR CIĄGŁY	NARODOWE CENTRUM NAUKI	MOZART	konkurs na polsko-austriackie projekty badawcze	https://www.ncn.gov.pl/ogloszenia/konkursy/mozart
6	17.06.2019-17.09.2019	NARODOWE CENTRUM NAUKI	SONATA BIS 9	konkurs na projekty badawcze mające na celu powołanie nowego zespołu naukowego, realizowane przez osoby posiadające stopień naukowy lub tytuł naukowy, które uzyskały stopień naukowy doktora w okresie od 5 do 12 lat przed rokiem wystąpienia z wnioskiem	na etapie opracowywania
7	17.06.2019-17.09.2019	NARODOWE CENTRUM NAUKI	MAESTRO 11	konkurs na projekty badawcze mające na celu powołanie nowego zespołu naukowego, realizowane przez osoby posiadające stopień naukowy lub tytuł naukowy, które uzyskały stopień naukowy doktora w okresie od 5 do 12 lat przed rokiem wystąpienia z wnioskiem	na etapie opracowywania
8	17.06.2019-17.09.2019	NARODOWE CENTRUM NAUKI	UWERTURA 4	konkurs na staże w zagranicznych zespołach naukowych realizujących granty ERC	na etapie opracowywania
9	16.09.2019-16.12.2019	NARODOWE CENTRUM NAUKI	OPUS 18	konkurs na projekty badawcze, w tym finansowanie zakupu lub wytworzenia aparatury naukowo-badawczej niezbędnej do realizacji tych projektów	na etapie opracowywania
10	16.09.2019-16.12.2019	NARODOWE CENTRUM NAUKI	PRELUDIUM 18	konkurs na projekty badawcze realizowane przez osoby rozpoczynające karierę naukową nieposiadające stopnia naukowego doktora	na etapie opracowywania
11	31.12.2019	MINISTERSTWO NAUKI I SZKOLNICTWA WYŻSZEGO	DIALOG	Celem programu jest wsparcie działań służących budowaniu współpracy i trwałych relacji między podmiotami działającymi w obszarze nauki a podmiotami działającymi w sferze społeczno-gospodarczej.	https://www.gov.pl/web/nauka/dialog
12	16.12.2019-16.03.2020	NARODOWE CENTRUM NAUKI	SONATINA 4	na projekty badawcze realizowane przez osoby posiadające stopień naukowy doktora, uzyskany w okresie do 3 lat przed rokiem wystąpienia z wnioskiem	na etapie opracowywania
13	16.12.2019-16.03.2020	NARODOWE CENTRUM NAUKI	ETIUDA 8	konkurs na stypendia doktorskie	na etapie opracowywania
14	01.07.2019	NARODOWE CENTRUM BADAŃ I ROZWOJU	SZYBKA ŚCIEŻKA - 2/1.1.1/2019	B+R (badania przemysłowe i/lub eksperymentalne prace rozwojowe, które mogą być uzupełnione o prace przedwdrożeniowe).	https://www.ncbr.gov.pl/programy/fundusze-europejskie/poir/konkursy/konkurs-21112019-szybka-sciezka/
15	16.04.2019	S.C.1-BHC-07-2019	Regenerative medicine: from new insights to new applications	Regenerative medicine replaces or regenerates human cells, tissue or organs, to restore or establish normal function. Projects should focus on innovative translational research to develop regenerative processes towards the ultimate clinical goal of addressing unmet clinical needs of large patient groups. Proposals should be based on new approaches such as genome editing or gene therapy, transdifferentiation or in vivo reprogramming, cell therapy and transplantation, 3D bioprinting, organoids or use of combined products (non-exhaustive list for illustrative purposes only).	http://ec.europa.eu/research/participants/portal/desktop/en/opportunities/h2020/topics/sc1-bhc-07-2019.html
16	16.04.2019	SC1-BHC-10-2019	Innovation Procurement: Next generation sequencing (NGS) for routine diagnosis	The objective is to implement NGS in routine diagnostics for personalised medicine and scale up demand-driven innovation for healthcare systems. This includes organisational, economical, technical and clinical aspects. It should lead to NGS tests, clinically validated procedures (including sex analysis), quality assurance schemes, tools and methods for data collection, management, analysis and interpretation, with a view to assist clinical decision-making and foster medical research and innovation. Transferability and cloud based NGS data analyses should be considered, as appropriate. Input from initiatives like the EJP Cofund on rare diseases and ERNs[1] should be considered when relevant. Ethical issues should be addressed.	http://ec.europa.eu/research/participants/portal/desktop/en/opportunities/h2020/topics/sc1-bhc-10-2019.html
17	16.04.2019	SC1-BHC-13-2019	Mining big data for early detection of infectious disease threats driven by climate change and other factors	It is expected that proposals develop: the technology to allow the pooling, access, analysis and sharing of relevant data, including next generation sequencing; the innovative bio-informatics and modelling methodologies that enable risk modelling and mapping; and the analytical tools for early warning, risk assessment and monitoring of (re-)emerging infectious disease threats.	http://ec.europa.eu/research/participants/portal/desktop/en/opportunities/h2020/topics/sc1-bhc-13-2019.html

18	16.04.2019	SC1-BHC-28-2019	The Human Exposome Project: a toolbox for assessing and addressing the impact of environment on health	Applicants should take advantage of the last decade's rapid technological advances which have opened up new opportunities to collect, combine and analyse large data sets offering new possibilities to understand the contribution of environmental factors to the global health burden of common chronic diseases. Proposals should use innovative approaches to the systematic and agnostic identification of the most important environmental risk factors for the development of major NCDs across the life course (including in utero), leading to preventive interventions at the individual, group or population level and contribute to sustainable healthcare.	http://ec.europa.eu/research/participants/portal/desktop/en/opportunities/h2020/topics/sc1-bhc-28-2019.html
19	16.04.2019	SC1-BHC-31-2019	Pilot actions to build the foundations of a human cell atlas	For better understanding human health as well as improving the diagnosis, monitoring and treatment of diseases, greater knowledge is needed of the diverse cells found within the human body. Recent developments in single cell technologies, analytical methods and computational tools allow for unprecedented characterisation of human cells. A novel approach to address this challenge is the international Human Cell Atlas initiative (HCA) which will create molecular reference maps of all human cells. The potential scientific scope and organisation, including the community values to be adhered to by participating researchers, are described in a recent white paper. Seasonal influenza is a major health burden, with an estimated 500,000 deaths around the world each year. A further threat from influenza is the non-seasonal emergence of new strains, which have the potential to result in major influenza pandemics. Despite the large danger posed by both seasonal and pandemic influenza, vaccines against flu are only moderately effective. In addition, current influenza vaccines need to be developed every year, as they only work against a narrow range of the hugely variable influenza subtypes, and are also highly vulnerable to strain mutations after an annual vaccine has been developed. Improved influenza vaccines would simultaneously ease a significant global health burden, and help the international community to better prepare in the event of an influenza pandemic.	https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/sc1-bhc-32-2019
20	16.04.2019	SC1-HCO-01-2018-2019-2020	Actions in support of the International Consortium for Personalised Medicine	Each action should focus on one of the following fields: 1. International aspect: The action should focus on building links with third countries by analysing the potential and advantages of collaboration in personalised medicine (PM). 2. Regional aspect: The action should establish and support networking between regions and interregional cooperation in different European countries. 3. Healthcare- and pharma-economic models for personalised medicine, interlinking European public health approaches with medical practice and financing. 4. Standardisation for clinical study design.	http://ec.europa.eu/research/participants/portal/desktop/en/opportunities/h2020/topics/sc1-hco-01-2018-2019-2020.html
21	16.04.2019	SC1-HCO-15-2019	Support for the functioning of the Global Research Collaboration for Infectious Disease Preparedness (GloPID-R)	Human health worldwide is increasingly threatened by potential epidemics caused by existing or newly emerging infectious diseases, including those that are resistant to antimicrobial agents. With globalisation, people movement and trade at record highs, pathogens can spread further and faster than ever before in human history. To fight such an international challenge, the EU must think globally and coordinate with international infectious disease research funders. It is for this reason that the Global Research Collaboration for Infectious Disease Preparedness (GloPID-R) was established in 2013 in response to a request for coordination by the Heads of International Research Organizations. Years on, GloPID-R now provides an important platform for infectious disease research funders to work together to better tackle deadly outbreaks such as Ebola, yellow fever, Zika and plague.	https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/sc1-hco-15-2019
22	24.04.2019	SC1-DTH-01-2019	Big data and Artificial Intelligence for monitoring health status and quality of life after the cancer treatment	Currently available methods and strategies for diagnosis and treatment of cancer help clinicians continuously improve quality of care and prevent cancer deaths in the population. Accurate risk assessment, availability of genetic tests, timely diagnosis and effective treatment has created the impression of cancer being a chronic disease that can be cured.	https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/sc1-dth-01-2019;freeTextSearchKeyword=:typeCodes=1;statusCodes=31094501,31094502,31094503;programCode=H2020;programDivisionCode=null;focusAreaCode=null;crossCuttingPriorityCode=null;callCode=H2020-SC1-DTH-2018-2020;sortQuery=openingDate;orderBy=asc;onlyTenders=false;topicListKey=topicSearchTablePageState
23	24.04.2019	SC1-DTH-05-2019	Large scale implementation of digital innovation for health and care in an ageing society	An ageing population is increasing demand-side pressures on public health and social care providers across Europe. These pressures undermine the long-term sustainability of existing models for delivering care services to the ageing population.	https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/sc1-dth-05-2019;freeTextSearchKeyword=:typeCodes=1;statusCodes=31094501,31094502,31094503;programCode=H2020;programDivisionCode=null;focusAreaCode=null;crossCuttingPriorityCode=null;callCode=H2020-SC1-DTH-2018-2020;sortQuery=openingDate;orderBy=asc;onlyTenders=false;topicListKey=topicSearchTablePageState
24	24.04.2019	SC1-DTH-09-2019	Scaling up the univocal Identification of Medicinal Products	Across the European Union, medicinal products display differences in names, variations in strength or their package size. The unavailability of a specific product may also necessitate substitution in many instances, if a patient is to be timely served in a pharmacy. Moreover, due to differences in marketing authorisation procedures, not every medicinal product is available in each Member State, and it is not unusual that the same product may have different names across Member States or the same name may identify a different product in another Member State.	https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/sc1-dth-09-2019;freeTextSearchKeyword=:typeCodes=0,1;statusCodes=31094501,31094502,31094503;programCode=null;programDivisionCode=null;focusAreaCode=null;crossCuttingPriorityCode=null;callCode=H2020-SC1-DTH-2018-2020;sortQuery=openingDate;orderBy=asc;onlyTenders=false;topicListKey=topicSearchTablePageState

25	24.04.2019	SC1-DTH-01-2019	Big data and Artificial Intelligence for monitoring health status and quality of life after the cancer treatment	Currently available methods and strategies for diagnosis and treatment of cancer help clinicians continuously improve quality of care and prevent cancer deaths in the population. Accurate risk assessment, availability of genetic tests, timely diagnosis and effective treatment has created the impression of cancer being a chronic disease that can be cured. However, often rather aggressive treatment, psychological stress (anxiety and depression) can cause physical and psychological problems that may cause long-term after-cure consequences such as similar or other types of cancer, other types of (chronic) diseases and affect the quality of life of a patient.	https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/sc1-dth-01-2019;freeTextSearchKeyword=;typeCodes=0,1,statusCodes=31094501,31094502,31094503;programCode=null;programDivisionCode=null;focusAreaCode=null;crossCuttingPriorityCode=null;callCode=H2020-SC1-DTH-2018-2020;sortQuery=openingDate;orderBy=asc;onlyTenders=false;topicListKey=topicSearchTablePageState
26	24.04.2019	SC1-DTH-05-2019	Large scale implementation of digital innovation for health and care in an ageing society	An ageing population is increasing demand-side pressures on public health and social care providers across Europe. These pressures undermine the long-term sustainability of existing models for delivering care services to the ageing population.	https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/sc1-dth-05-2019;freeTextSearchKeyword=;typeCodes=0,1,statusCodes=31094501,31094502,31094503;programCode=null;programDivisionCode=null;focusAreaCode=null;crossCuttingPriorityCode=null;callCode=H2020-SC1-DTH-2018-2020;sortQuery=openingDate;orderBy=asc;onlyTenders=false;topicListKey=topicSearchTablePageState
27	29.04.2019	ERA-CVD/NCBIR	4. konkurs w ramach ERA-CVD Cardiovascular Diseases	14 stycznia br. otwarto nabór wniosków w ramach 4. międzynarodowego konkursu organizowanego w ramach programu ERA-CVD Cardiovascular Diseases. Konkurs skupia się na finansowaniu badań obejmujących zagadnienia z zakresu chorób sercowo-naczyniowych przez młodych naukowców.	https://www.ncbr.gov.pl/o-centrum/aktualnosci/szczegoly-aktualnosci/news/otwarcie-naboru-wnioskow-w-4-konkursie-w-ramach-era-cvd-cardiovascular-diseases-54113/
28	24.05.2019		AAL 2019 Call Programu AAL	The aim of the call is to support innovative, transnational and multi-disciplinary collaborative projects. Call 2019 is characterised by the following approach: The AAL Call 2019 is open to developing ICT-based solutions targeting any application area(s) within the AAL domain. The solutions need to be embedded in the strategies of the participating end-user organisations, service providers and business partners. The AAL Call 2019 allows for more flexibility regarding the scope, size and duration of the proposed projects (including small collaborative projects).	http://www.aal-europe.eu/stay-up-to-date/calls/call-challenge-2019/